Sai Parenterals Ltd., a diversified pharmaceutical formulations company, on Tuesday, March 17, announced that it has set the price band for its proposed initial public offering (IPO) at ₹372–₹392 per share.
The company has filed its Red Herring Prospectus (RHP) with the Securities and Exchange Board of India (SEBI) and the stock exchanges in preparation for the offering. The IPO comprises a fresh issue of equity shares worth up to ₹285 crore, along with an offer-for-sale (OFS) of nearly 32 lakh shares. The company plans to list its equity shares on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).
Proceeds from the IPO are expected to fund the next phase of the company’s growth, with a strong emphasis on expanding its global formulations business and enhancing its Contract Development and Manufacturing Organisation (CDMO) capabilities across injectable products as well as oral solid dosage forms.
Also Read: Upcoming IPO: SEBI Clears IPO Plans Fab Hotels, Tea Post and Learnfluence Education
Sai Parenterals operates as a diversified pharmaceutical formulations player with integrated capabilities spanning research, development, and manufacturing. Its business is broadly divided into two segments: branded generic formulations and CDMO products and services catering to both domestic and international markets.
The company’s product portfolio covers a wide range of therapeutic areas, including cardiovascular care, neuropsychiatry, anti-diabetic treatments, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. These offerings are available in multiple dosage forms such as injectables, tablets, capsules, liquid orals, and ointments, reflecting the company’s broad manufacturing and formulation expertise.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Mar 18, 2026, 9:29 AM IST
Sachin Gupta
Sachin Gupta is a Content Writer with 6+ years of experience in the stock market, including global markets like the US, Canada, and Australia. At Angel One, Sachin specialises in creating financial content that simplifies complex market trends. Sachin holds a Master's in Commerce, specialising in Economics.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
